Question 11190 — pharmacy and medications

Summary

Mr. Fabrice Barusseau alerts the Minister of Health, Families, Autonomy and Disabled People to the consequences of poorly adapted vaccination coverage. A certain number of particularly vulnerable people wish to protect themselves from seasonal flu with a high-dose vaccine, better suited to their needs. However, the Efluelda vaccine, produced in France by Sanofi and which contains four times more hemagglutinin per strain viral than traditional flu vaccines, appears to no longer be available in some pharmacies. Efluelda could not be used for the 2024-2025 campaign due to a disagreement over the price between Sanofi and the French authorities: the laboratory requested a price of around 30 euros, or three times more than the reference flu vaccines. Thus, he asks him to confirm whether the Efluelda vaccine is currently marketed for the flu vaccination campaign in France, to specify the access arrangements for vulnerable people, particularly in rural areas and in local pharmacies, and to specify whether localized supply shortages have been identified. Finally, he wishes to know the measures envisaged in the short term to guarantee that all vulnerable people can benefit from a vaccine maximum effectiveness anti-flu.

Machine translation from French. The official text remains authoritative.

Timeline

1. 25 November 2025

   Question

   Source: DateQuestion

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

• Fabrice Barusseau · auteur

Related records

No cross-record relationships stored yet.